Clinical Trials Logo

Clinical Trial Summary

Budd-Chiari syndrome (BCS) is defined as the hepatic outflow obstruction from the small hepatic veins to the confluence between inferior vena cava and right atrium, which often leads to the life-threatening complications, such as liver failure and portal hypertension-related complications. At present, a stepwise treatment strategy is employed, including anticoagulation, thrombolysis, percutaneous recanalization (i.e., percutaneous transluminal angioplasty [PTA] alone or in combination with stent placement), transjugular intrahepatic portosystemic shunt, and liver transplantation. In West, only less than 20% of BCS patients underwent percutaneous recanalization; by contrast, percutaneous recanalization is the most common treatment modality used in China.

Recently, an 11-year retrospective case series of 177 Chinese patients with primary BCS has shown a higher rate of re-occlusion in the PTA alone group than in the PTA combined with stent placement group (31% versus 7.7%, p<0.001). In addition, re-occlusion was regarded as the independent predictor of mortality. Accordingly, we hypothesized that PTA alone might have a worse survival than PTA combined with stent placement in Chinese patients with primary BCS.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02201485
Study type Interventional
Source Fourth Military Medical University
Contact
Status Completed
Phase N/A
Start date May 2014
Completion date April 2019

See also
  Status Clinical Trial Phase
Completed NCT05117684 - To Compare "Balloon Occluded Thrombolysis" With "Conventional Catheter Directed Thrombolysis" in Thrombotically Occluded DIPSS Stent in Patients of Budd- Chiari Syndrome.
Recruiting NCT03541057 - Vienna Vascular Liver Disease Study
Recruiting NCT06054451 - Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India